

Division of Clinical Haemato-Oncology

Giovanni MARTINELLI, MD
Director

STAFF Co-Director Div. Haemato-oncology and Director of Allogeneic

Transplantation Unit: Fedro Peccatori, MD, PhD

Deputy Directors: Emilia Cocorocchio, MD, Daniele Laszlo, MD, Rocco Pastano, MD

Senior Assistants: Alberto Agazzi, MD, Alessandra Alietti, MD

Assistants: Anna Vanazzi, MD, Simona Bassi, MD,

Paola Bertazzoni, MD, Federica Gigli, MD

Fellows: Luca Nassi, MD, Simona Sammassimo, MD

Visitors: Prof. Enzo Bonmassar, MD, Sara Steffanoni, MD

Data Manager: Liliana Calabrese, Biological Science

Data Manager fellows: Rosaria Cascio, Pharmacology and Mara Negri, Biological Science

Collaborator: Maria Teresa Lionetti

Secretaries: Daniela Antoniotti, Tiziana Masala, Patrizia Passeri

Head Nurse: Angela Cocquio

Scientific nurses: Sarah Liptrott, Laura Orlando

Nurses: Aleksandra Babic, Cristina Berti, Luca Casellato,

Gloria Cavedini, Margherita Clerici, Claudio Di Leverano,

Rossana D'Oria, Cristina Grossi, Bruno Lucchetti,

Roberta Magri, Francesca Rossetti, Lara Roveda, Enrico Sari

Auxiliaries: Antonella Autiero, Romina Bianco,

Francesca Di Titta, Antonella Ferrari, Dania Infante,

Patrizia Lombardi, Mihaela Mirošanu

Activities 2007. Our mainstream is treatment of leukemia, lymphoma, Hodgkin's disease, multiple myeloma and improve the quality of life of patients and their families. At one time, only few people affected by these diseases survived. Now, thanks to advances in treatments, more than 60 % of patients are cured successfully. Thus, a new challenge arises: the study of the long-term effects of treatments.

During the last year, a scientific committee (The Ematoncologia Scientific Committee) was designed to provide a forum for planning, implementation, co-ordination and ongoing review of clinical research trials (interventional and non-interventional) conducted within the Division

of Ematoncologia at the IEO, in line with Good Clinical Practice (ICH-GCP) and the IEO research strategy (our mission statement). We have a core team membership, which includes medical staff, statistician, research nurses, head-nurse, laboratory staff and data management. Other members are invited according to the protocols being discussed.

In 2007, the committee examined 32 new projects: 21 accepted, 7 in process, 4 rejected.

Within the Division of Clinical Haemato-Oncology, the Allogeneic Transplant Unit performs allogeneic transplant with reduced conditioning or myeloablative regimens, both from sibling and random donors principally, for patients with haematologic malignancies. The Unit has been accredited within BMDR for marrow unrelated donor transplantation and has applied for Jacie accreditation. In 2007, 64 autologous and 7 allogeneic transplantations were performed. Our team is also currently working with immunotherapies to treat non-Hodgkin lymphoma (NHL). Our clinical results showed that the combination of immunotherapy with conventional chemotherapy regimens led to improvements in response rates in NHL. Radio-labelled immunotherapy, which combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, is promising to be a major step forward in the treatment of malignant lymphomas and because of an improved tolerability may allow transplantation in wider patient groups in the future than previously feasible.

The Division published other two studies carried out with clinical international groups. One, within the International breast Cancer study group, for investigating the quality of life of premenopausal patients receiving chemotherapy, hormonotherapy or their combination and the other within the International extranodal lymphoma study group, for describing clinical features, prognostic factors, patterns of failure and treatment outcomes in primary diffuse large B cell lymphomas of breast, a rare localized extranodal non-Hodgkin lymphoma presentation.

Young people are welcome to join us. Two new grants were awarded in fiscal year 2007 for a contribution in Clinical

Clinical Haemato-Oncology

| | | | |
|----------------|--------|----------------|-------|
| Admissions | | Day Hospital | |
| Admissions | 547 | Cycles | 273 |
| -Surgery Adm | 75 | -Surgery Cyc | - |
| -Medical Adm | 472 | -Medical Cyc | 273 |
| Surgical Index | 13,71% | Surgical Index | 0,00% |
| Days | 3-354 | Treatments | 1.262 |
| Alos | 6,13 | Alos Treat | 4,62 |
| ARW | 2,10 | ARW | 1,00 |



and histological characterization of Graft versus disease in allogeneic transplanted patients and in immunotherapy and radio-immunotherapy in the treatment of malignant lymphomas

The Division has started up an Haemostasis-Clotting at patient unit. This intra-divisional activity provides assistance and guidance in resolving problems due to haemostasis and thrombosis in oncological patients at IEO.

Communities get benefit from a spirit of collaboration and co-operation between local Governments and health institutions. In this framework, our research group was invited for a membership in REL, a network established by Lombardy Region for optimizing assistance and cure for patients

affected by haematological disease. REL also defines criteria for the accreditation of transplant centres operating at regional level.

In 2007, our team produced 21 articles published on scientific journals with an overall impact factor of 122 points.